Live tape
Top 8, mentions 7d15,947NVDA5,736 mentions▲ +0.04GOOGL2,193 mentions▲ +0.05SPY1,842 mentions▲ +0.05QQQ1,638 mentions▲ +0.05AMD1,330 mentions▲ +0.08SPCX1,313 mentions▲ +0.05TSLA1,010 mentions▲ +0.05SNDK885 mentions▲ +0.06

Equity · Healthcare

LTRN

NASDAQ

Lantern Pharma (LTRN)

2.89 USD −1.37% vs prior close
Lantern Pharma Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
36.9M USD
EPS, diluted, year to Dec 2025
−1.57 USD
52-week range
1.03 USD – 5.50 USD
Avg volume
34.3K

as of Jul 17, 2026

Have Lantern Pharma (LTRN) insiders bought or sold shares recently?

LTRN's newest Form 4 filing is dated 12 May 2026: none in the last 90 days.

Form 4

Have Lantern Pharma (LTRN) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
12 May 2026Schalop Lee TroyDirectorBuy48,544100K USD
12 May 2026KEYSER D JEFFREYDirectorBuy48,544100K USD
Bought2 open-market purchases97,088$200K

Which funds hold Lantern Pharma (LTRN)?

3 of the 45 institutional funds we track reported a Lantern Pharma position for the quarter ended 30 Jun 2026 — a combined 1.5M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Lantern Pharma (LTRN)?
FundPositionSharesValueShares q/q
Renaissance TechnologiesAdded291,0391.2M USD+150.9%
Citadel AdvisorsNew position47,895200K USD
Marshall WaceNew position11,94650K USD

What has been filed or recorded for Lantern Pharma (LTRN)?

The filings we hold for Lantern Pharma, newest first: 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Jun 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Lantern Pharma (LTRN)?
And
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.57 USD
30 Jun 2026FinancialsTotal assets8.6M USDat period end
30 Jun 2026FinancialsTotal equity−3.2M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.30 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.57 USD
31 Dec 2025FinancialsNet income−17.1M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.57 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.39 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.40 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.42 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.93 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.42 USD

What do people ask about Lantern Pharma (LTRN)?

From live data
What is Lantern Pharma’s market cap?36.9M

Lantern Pharma is worth 36.9M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

Have Lantern Pharma insiders bought or sold shares recently?

No Lantern Pharma insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 12 May 2026 (SEC Form 4). See Insiders

Which funds own Lantern Pharma?3 of 45

3 of the 45 funds we track reported a Lantern Pharma position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Citadel Advisors and Marshall Wace. See Funds

When did Lantern Pharma last report earnings?−0.57

Lantern Pharma last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.57 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  6. SEC EDGARreported earnings figures and scheduled report dates
  7. SEC EDGARValuation computed from SEC EDGAR filings